Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 29:24:100334.
doi: 10.1016/j.metop.2024.100334. eCollection 2024 Dec.

Higher levels of plasmatic saturated fatty acid were significantly associated with liver fibrosis in HIV mono-infection: A case-control study

Cristiane Fonseca de Almeida  1   2 , Wilza Arantes Ferreira Peres  3 , Paula Simplício da Silva  1   2 , Claudia Santos de Aguiar Cardoso  1   2 , Michelle Morata de Andrade  4 , Julio Castro-Alves  4 , Marcel de Souza Borges Quintana  4 , Marina Campos Araujo  5 , Karla Yasmin Dias Fraga  3 , Julliana Antunes Cormack  1   2 , Ronaldo Ismerio Moreira  6 , Sandra W Cardoso  6 , Valdilea G Veloso  6 , Beatriz Grinsztejn  6 , Patricia Dias de Brito  1   2 , Hugo Perazzo  6
Affiliations

Higher levels of plasmatic saturated fatty acid were significantly associated with liver fibrosis in HIV mono-infection: A case-control study

Cristiane Fonseca de Almeida et al. Metabol Open. .

Abstract

Background: The relationship between plasmatic fatty acid (FA) composition and liver fibrosis remains scarce in people living with HIV/AIDS (PLWHA). We aimed to evaluate the association of plasmatic FAs and liver fibrosis in HIV mono-infected individuals.

Methods: This case-control study included PLWHA with liver fibrosis (cases) and randomly selected subjects without fibrosis (controls) from the PROSPEC-HIV study (NCT02542020). Participants with viral hepatitis, abusive alcohol consumption and lipid supplements use were excluded. Liver fibrosis was defined using transient elastography (TE) by liver stiffness measurement (LSM) ≥ 7.1 kPa or ≥ 6.2 kPa with M or XL probe, respectively. All HIV mono-infected participants with liver fibrosis identified at the baseline PROSPEC-HIV visit were included. Controls (1:1) were randomly selected among those HIV mono-infected participants without liver fibrosis. Plasmatic FA profile, dietary lipid intake, anthropometric measures, and blood samples were assessed. Plasmatic fatty acid was analyzed using gas chromatography and intake of fats lipids were assessed by two 24-h dietary recall (24-HDR). Multivariate logistic regression models adjusted by age, sex at birth and duration of antiretroviral therapy (ART) were performed.

Results: A total of 142 participants (71 cases and 71 controls) [62 % female, median age = 46 (IQR, 37-53) years, 14.8 % with diabetes, median CD4 count = 655 cells/mm3, 96.5 % under ART] were included. Higher percentages of plasmatic palmitc acid (16:0) and saturated fatty acids (SFA) were observed in participants with liver fibrosis (cases) compared to those without (controls). Presence of higher percentage of plasmatic palmitc acid (16:0) was associated with an increased odds for liver fibrosis [adjusted OR = 1.23 (95%CI 1.04-1.46); p = 0.02] in multivariate models.

Conclusion: This study showed the potential role of the plasmatic FA composition in the pathogenesis of liver fibrosis in PLWHA.

Keywords: Fatty acid composition; HIV infection; Liver fibrosis; NAFLD.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Flow-chart of the study.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Devarbhavi H., Asrani S.K., Arab J.P., Nartey Y.A., Pose E., Kamath P.S. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516–537. doi: 10.1016/j.jhep.2023.03.017. - DOI - PubMed
    1. Younossi Z., Anstee Q.M., Marietti M., Hardy T., Henry L., Eslam M., et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20. doi: 10.1038/nrgastro.2017.109. - DOI - PubMed
    1. Ullah R., Rauf N., Nabi G., Ullah H., Shen Y., Zhou Y.-D., et al. Role of nutrition in the pathogenesis and prevention of non-alcoholic fatty liver disease: recent updates. Int J Biol Sci. 2019;15:265–276. 10/gf6d67. - PMC - PubMed
    1. Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatol Baltim Md. 2023;78:1966. doi: 10.1097/HEP.0000000000000520. - DOI - PMC - PubMed
    1. Perazzo H., Pacheco A.G., Griep R.H., Gracindo R., Goulart A.C., Fonseca M de JM da. Changing from NAFLD through MAFLD to MASLD: similar prevalence and risk factors in a large Brazilian cohort. J Hepatol. 2024;80:e72–e74. doi: 10.1016/j.jhep.2023.08.025. - DOI - PubMed

LinkOut - more resources